AstraZeneca PLC Director/PDMR Shareholding (0977S)
December 16 2016 - 8:00AM
UK Regulatory
TIDMAZN
RNS Number : 0977S
AstraZeneca PLC
16 December 2016
16 December 2016 13:00
Transaction by a Person Discharging Managerial
Responsibilities
Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse
Regulation
On 16 December 2016, Pascal Soriot, a Director of the Company,
notified us that, on 16 December 2016, he ceased to be beneficially
interested in 59,951 AstraZeneca PLC Ordinary Shares of $0.25 each
as a result of a gift of those shares to family members for nil
consideration.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Pascal Soriot
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------- ------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name AstraZeneca PLC
--- ------------------------- ------------------------------------
b) LEI Not applicable
--- ------------------------- ------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of Ordinary Shares of US$0.25
the financial each in AstraZeneca PLC
instrument, type
of instrument
GB0009895292
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the Gift of shares to family
transaction members for nil consideration
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
0 59,951
--------- ----------
--- ------------------------- ------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 16 December 2016
--- ------------------------- ------------------------------------
f) Place of the transaction London
--- ------------------------- ------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUNVARNBAUAAA
(END) Dow Jones Newswires
December 16, 2016 08:00 ET (13:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024